Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma

Documenti analoghi

• Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission
  di: Brian H. Kushner, et al.
  Pubblicazione: (2026)
• A phase II trial of naxitamab plus stepped‐up dosing of GM ‐ CSF for patients with high‐risk neuroblastoma in second or later complete remission
  di: Brian H. Kushner, et al.
  Pubblicazione: (2026)
• Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti‐GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
  di: Wei Wei, et al.
  Pubblicazione: (2025)
• Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients
  di: Michal Kyr, et al.
  Pubblicazione: (2024)
• Breast conserving surgery with intraoperative electron beam radiation therapy for low‐risk breast cancer: Five‐year follow‐up of 306 patients
  di: Charlotte de Jonge, et al.
  Pubblicazione: (2024)